Cervical Cancer

06 October 2011

Synthetic oestrogens cause fertility problems

Women whose mothers took synthetic oestrogens called DES before it was discontinued in 1971 have been found to suffer from fertility problems and cancers, according to a study.

0

Women whose mothers took a synthetic oestrogens called DES before it was discontinued in 1971 have been found to suffer from a variety of fertility problems and cancers, according to a major new study.

The study appearing in New England Journal of Medicine examines the daughters of females exposed in the womb to diethylstilbestrol (DES), which was prescribed in the mistaken belief it could reduce certain complications of pregnancy.

Researchers at the National Cancer Institute and several other medical centres followed some 6,500 women, including 4,600 exposed to DES.

They concluded that the daughters with exposure to DES in the womb had an increased risk of 12 medical conditions, including a twofold higher risk of infertility and a fivefold increased risk of having a preterm delivery.

Cancer of the vagina

The women also had 40 times the risk of developing a rare cancer of the vagina among young women, called clear cell adenocarcinoma – although the number of cases remains around one in 1,000, the researchers said.

The follow-up of a 1992 study aimed to get better information on the health risks of DES, which was first prescribed in 1940 in the United States. Between five million and 10 million pregnant women and babies had been exposed to the drug in various forms, including pills, creams and vaginal suppositories.

"Our study carefully documents elevated risk for DES-exposed daughters for a host of medical problems – many of them also quite common in the general population," said study author Robert Hoover at the cancer institute, part of the National Institutes of Health.

"Without the sentinel finding of a very rare cancer in young women, and without the sustained follow-up of those who were exposed, we would not know the full extent of harm caused by DES exposure in the womb."

Breast cancer likely too

The study is the first to estimate the cumulative proportion of all DES-exposed women who developed these conditions because of their exposure, the scientists said.

The study concluded that one in five DES-exposed daughters will experience some level of infertility because of their exposure.

While the first women diagnosed with the rare cancer in the late 1960s were adolescents and young adults at the time of their diagnosis, the research now shows that the risk for DES-exposed daughters continues through at least age 40.

In addition, these women are more than twice as likely to develop pre-cancerous cells in the cervix or vagina and have an 80% higher chance of developing breast cancer after age 40.

Testicular abnormalities in sons

By age 55, according to the researchers one in 25 DES-exposed daughters will develop abnormal cellular changes in the cervix or vagina, and one in 50 will develop breast cancer due to their DES exposure.

This study did not evaluate sons with DES exposure in the womb, but previous reports have indicated an increased risk for certain testicular abnormalities, including undescended testicles. So far, research has shown no decreased fertility for these men, even with testicular abnormalities.

The other research centres involved in this work are Boston University Slone Epidemiology Centre; Cedars-Sinai Medical Centre DES Project; University of Chicago Department of Obstetrics and Gynaecology; Dartmouth-Hitchcock Medical Centre; The Mayo Clinic DES Project; The Methodist Hospital-Research Institute Department of Obstetrics and Gynaecology; and Tufts Medical Centre.

(Sapa, October 2011) 

Read more:

Fertility

Testicular cancer

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.

Ask the Expert

Cancer expert

CANSA’s purpose is to lead the fight against cancer in South Africa. Its mission is to be the preferred non-profit organisation that enables research, educates the public and provides support to all people affected by cancer. Questions are answered by CANSA’s Head of Health Professor Michael Herbst and Head of Advocacy Magdalene Seguin. For more information, visit cansa.org.za.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules